Adynxx announces May 29, 2019 as payment date of previously announced special cash dividend of $1.05 per share to former Alliqua shareholders Adynxx confirms intent to consummate the previously...
SAN FRANCISCO, May 06, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
LANGHORNE, Pa., April 22, 2019 (GLOBE NEWSWIRE) -- Dear Shareholder: On January 3rd, I wrote a letter updating you, our shareholders, on the status of events that I thought would affect...
LANGHORNE, Pa., April 11, 2019 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) announced today that its Board of Directors has declared a special cash dividend of $1.05 for each...
LANGHORNE, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- To our Alliqua Shareholders: I hope you have seen our recent exciting announcements that we believe drove the increase in our market...
LANGHORNE, Pa., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) and TO Pharmaceuticals LLC, a privately held cannabinoid-based pharmaceutical therapy company (“TOP”...
Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation PR Newswire LANGHORNE, Pa...
Alliqua to return capital to shareholders Alliqua Retains H.C. Wainwright and Co. to evaluate strategic options LANGHORNE, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc...
YARDLEY, Pa., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (NASDAQ:ALQA) (“Alliqua or the “Company”), a regenerative technologies company committed to restoring tissue and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.